Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,516 | $1,430 | $1,668 | $3,043 |
| - Cash | $48 | $52 | $74 | $431 |
| + Debt | $23 | $22 | $23 | $23 |
| Enterprise Value | $1,490 | $1,400 | $1,617 | $2,635 |
| Revenue | $10 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $9 | $0 | $0 | $0 |
| % Margin | 95% | – | – | – |
| EBITDA | -$24 | -$45 | -$34 | -$29 |
| % Margin | -238.1% | – | – | – |
| Net Income | -$24 | -$34 | -$24 | -$20 |
| % Margin | -243.1% | – | – | – |
| EPS Diluted | -0.39 | -0.55 | -0.38 | -0.36 |
| % Growth | 29.1% | -44.7% | -5.6% | – |
| Operating Cash Flow | -$13 | -$24 | -$17 | -$17 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$13 | -$24 | -$17 | -$17 |